Sanctuary Advisors LLC Acquires Shares of 39,923 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Sanctuary Advisors acquired 39,923 Regeneron shares in the second quarter, valued at approximately $24.9 million. Institutional investors own 83.31% of REGN.
• Analysts maintain a “Moderate Buy” consensus, with 16 Buy ratings and 10 Holds and an average price target of $801.70, despite several recent target reductions.
• Regeneron reported quarterly EPS of $14.29 and revenue of $4.29 billion, beating estimates, while its pipeline gained potential from FDA approval of Pasatru and an obesity-treatment program. The company also faces investor litigation tied to alleged disclosures surrounding its Fianlimab-Libtayo melanoma trial.

Sanctuary Advisors LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 39,923 shares of the biopharmaceutical company's stock, valued at approximately $24,894,000.

Other hedge funds also recently made changes to their positions in the company. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $26,000. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $29,000. Kemnay Advisory Services Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $31,000. Finally, Birchwood Financial Partners Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $32,000. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. Canaccord Genuity Group reduced their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating on the stock in a research report on Tuesday, May 19th. Citigroup boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a "neutral" rating in a research report on Monday, August 3rd. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. Finally, BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a research note on Monday, May 18th. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $801.70.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $834.04 on Monday. The firm has a market capitalization of $85.87 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 1.42 and a beta of 0.21. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The business's 50-day moving average price is $697.09 and its 200-day moving average price is $716.46. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm's revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $12.81 earnings per share. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares of the company's stock, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the sale, the director owned 603 shares of the company's stock, valued at $482,400. The trade was a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is currently owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source